Theralase Technologies Inc. V.TLT

Looks like BTD for Q4

[Kayz88]

https://seekingalpha.com/article/4697875-theralase-technologies-inc-tltff-q1-2024-earnings-call-transcript

Clinical Data:

• Bladder Cancer Study Results: The Phase II study showed a 63% complete response rate and a 71% total response rate among patients, indicating effective destruction of bladder cancer.
• Secondary Objective: 33% of patients maintained a complete response for 15 months, improving to 34% with the optimized procedure.
• Safety: 13 serious adverse events were reported, none linked to the Theralase drug or device.
• Theralase Performance: Demonstrated a 57% complete response at 6 months, 35% at 12 months, and 34% at 15 months, surpassing guidelines for BCG-unresponsive bladder cancer.

Future Plans and Questions:

1. Study II Completion: Expected by end of 2024, with data lock by mid-2026 and potential FDA and Health Canada approval by end of 2026.
2. Comparison to Competition: Theralase's data is competitive, with better or comparable results to larger companies' treatments, at a significantly lower cost.
3. Patient Enrollment: Delayed due to FDA requests but expected to increase post-summer with strategic initiatives.
4. Breakthrough Designation: Ongoing updates and data collection for FDA submission expected in Q3 2024. BTD approval for Q4 2024. 
5. Partnerships: Aim to finalize partnerships or acquisition deals by end of 2026.
6. Other Cancer Studies: Preclinical work completed for brain cancer and ongoing for lung and blood cancers. Clinical trials planned for 2024-2025.
7. COVID-19 and Other Research: Transitioned focus from COVID-19 vaccine to an avian influenza vaccine and developing a topical treatment for herpes simplex.

Company Focus:

• Capitalization, patient enrollment, achieving breakthrough designation, regulatory approvals, and successful partnerships by 2026.
• Additional clinical studies and developing treatments for other cancers and diseases.

[Tarbaby]

XRAY ACTIVATED RUTHERRIN.. Has now been shown to stop agressive cancer in mouse lungs..same process can do same for human lung cancer.. Then proceed onto many other cancers that need a cure.. its a unique treatment in the cancer field. Big future for this company...imo